title: Pancreatic Cancer Registry in Japan: 20 years of experience.
abstract: The prognosis of pancreatic cancer is defined by the histology and extent of disease. Preoperative histologic diagnosis and diagnostic imaging are fundamentals in managing the disease, but it is not rare to find unexpected peritoneal dissemination or liver metastasis at the time of operation. The overall resectability rate of pancreatic cancer is 40% in Japan. Resecting the portal vein and peripancreatic plexus were performed on 40% of the patients who underwent pancreatectomy for invasive cancer in the head of the pancreas. Long-term survival was only found in patients who underwent pancreatectomy. Radical lymph node dissection, or combined resection of the large vessels, did not seem to improve survival further than the standard resection. Multidisciplinary treatments combined with surgery were performed, and various effects of postoperative chemotherapy after pancreatectomy, intraoperative- and postoperative-radiation therapy, or postoperative chemotherapy for unresectable tumor, were shown. Development of unconventional therapies and refinement of the conventional therapy should be promoted on a randomized prospective trial basis. To promote this effort, which requires the international comparisons and cooperation, JPS developed a computerized JPS registration system downloadable from the JPS website (http://www.kojin.or.jp/suizou/index.html).
authors.affiliation: Department of Gastroenterological Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan. smatsuno@surg1.med.tohoku.ac.jp
authors.forename: Seiki
authors.initials: S
authors.lastname: Matsuno
authors.forename: Shinichi
authors.initials: S
authors.lastname: Egawa
authors.forename: Shoji
authors.initials: S
authors.lastname: Fukuyama
authors.forename: Fuyuhiko
authors.initials: F
authors.lastname: Motoi
authors.forename: Makoto
authors.initials: M
authors.lastname: Sunamura
authors.forename: Shuji
authors.initials: S
authors.lastname: Isaji
authors.forename: Toshihide
authors.initials: T
authors.lastname: Imaizumi
authors.forename: Shuichi
authors.initials: S
authors.lastname: Okada
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kato
authors.forename: Kouichi
authors.initials: K
authors.lastname: Suda
authors.forename: Akimasa
authors.initials: A
authors.lastname: Nakao
authors.forename: Takehisa
authors.initials: T
authors.lastname: Hiraoka
authors.forename: Ryo
authors.initials: R
authors.lastname: Hosotani
authors.forename: Kazunori
authors.initials: K
authors.lastname: Takeda
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007564:Japan; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D012042:Registries; D016019:Survival Analysis